In half a year, heavy new drugs appear frequently, and nervous system diseases are frequently used

With the deepening of social aging, the incidence rate of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease is also increasing The market situation of nervous system diseases in recent years has also corroborated this From the perspective of market performance of sample hospitals, the growth rate of overall domestic drug sales has slowed down from 20% in the past few years to about 10% In 2016, the market scale of nervous system drugs in China reached 15.17 billion yuan, ranking fifth in all fields, with a year-on-year growth of 9.7% At the same time, in 2017, the number of drugs under research in the global nervous system continued to increase, from 2513 in 2016 to 2542 this year, although the growth rate was only 1.2%, slowing down compared with previous years In the first half of 2017, FDA approved a total of 28 new drugs for nervous system in 2017h1, which is even more than that in 2016 Among the 16 new molecular entities (NME), the drug use in nervous system accounted for the most 5; among the 10 biological products licensing applications (BLA), the drug use in nervous system diseases accounted for 2 The new Parkinson drug Xadago (Safinamide) is a chronic neurodegenerative disease which is the incidence rate of Alzheimer's disease in the elderly The incidence rate of Parkinson's disease is rising However, the number of anti Parkinson drugs is still few There is no cure yet Xadago (safinamide, safinamide), developed by Zambon and newron pharmaceutical company in Italy, was approved by FDA in March this year as a combination treatment drug of levodopa or carbidopa, which is also the first drug approved by American new drug market for Parkinson's disease in more than ten years In clinical trials, the efficacy of xadago has been confirmed, which can effectively improve the decline of motor ability caused by the use of levodopa At present, xadago has been listed in several European countries one after another After the loss of patent protection of its competitive product, azicollect (rasagiline), in 2017, some analysts predict that the annual sales volume will reach 450 million euros Deuterium drug austedo on April 3, 2017, FDA officially approved the Huntington chorea drug austedo of Teva company, which is a small molecule oral inhibitor targeting VMAT-2 It is also the first deuterium drug approved by FDA The effective component of austedo is infliximab Abda, which is the deuterium product of infliximab The drug was initially developed by auspex pharmaceuticals, a pharmaceutical company focusing on the research and development of deuterium instead of deuterium After that, auspex was acquired by Teva, and the drug also entered Teva The drug ingrezza ingrezza (valbenazine) is also a new type of VMAT2 inhibitor It is also the first drug approved by the FDA for the treatment of adult tardive dyskinesia (TD) It has obtained the breakthrough treatment recognition and priority approval right issued by the US FDA Interestingly, the drug has a similar structure to Teva's austedo, but does not have a black box warning of "may lead to depression and suicidal thoughts", and ingrezza's first listing also gives it a market advantage In fact, according to e valuepharma's forecast data of drug sales in 2022, ingrezza's sales are expected to reach 971 million US dollars On May 6, radicava, a new ALS drug, was approved by the FDA to be the first new drug for ALS therapy in the United States for 22 years Radicava (Edaravone) was listed for the treatment of ALS MT Pharma America's radicava is a neuroprotective agent that can scavenge free radicals to protect nerves from oxidative stress and neuronal apoptosis Before it was approved by the FDA, the drug had been first listed in Japan, and obtained the qualification of orphan drugs under the FDA method The potential "heavy explosive" ocrevus ocrevus is a monoclonal antibody of CD20 antigen inhibitor of B cell for recurrent multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) developed by gene tech company of Roche It is also the first PPMs drug approved by FDA E valuate Pharma, a medical market research company, forecasts that ocrevus will have annual sales of $2.7 billion by 2020 As early as February 2016, the drug has obtained the breakthrough drug qualification (BTD) granted by FDA As an intravenous infusion drug, ocrevus only needs to inject once every six months, which can greatly meet the clinical needs According to the prediction, the annual sales of the drug can easily reach 1 billion US dollars in the treatment of PPMS alone, which is a full "heavy explosive" In the global drug market, the typical drug enterprises of nervous system disease in China have been taking up a large proportion in the field of nervous system medicine In China, the proportion of the field in the medical terminal and clinical use is also gradually increasing In the future, under the situation of more and more fierce market competition, the market of nervous system medicine will be a hot spot for drug enterprises to compete for profits Anhua pharmaceutical Jiangsu Anhua Pharmaceutical Co., Ltd is a leading enterprise in the field of central nervous drugs in China It is also the only enterprise in the same industry in China that focuses on the drug market segment of central nervous system It has established a complete product line and sales network of central nervous drugs Enhua pharmaceutical, founded in 1999, was listed on A-share of small and medium-sized board of Shenzhen Stock Exchange on July 23, 2008 In the first half of 2017, its total operating revenue was 1.68 billion yuan, up 10.79% year-on-year, slightly higher than Q1 According to the semi annual report of Enhua pharmaceutical industry, the growth rate of the revenue of narcotic drugs was 7.59% year on year, of which the market potential of dexmedetomidine was huge In 2016, the sales volume of dexmedetomidine in sample hospitals reached about 500 million yuan, with a growth rate of 40.54% year on year LVYE Pharmaceutical Group Co., Ltd., founded in 1994, was the boss of the main board of Hong Kong in 2014 Among its products on the market, there are kingspin (slejilan) for the treatment of primary Parkinson's disease and the only FDA approved imitation of carbalatin transdermal preparation for the treatment of Alzheimer's disease According to the annual report of green leaf pharmaceutical, the company's turnover in 2016 was 2.918 billion yuan, and its net profit was 894 million yuan, an increase of 18.2% year on year Zuelacetam is a promising antiepileptic drug developed by Belgium UCB company and first listed in China in 2006 The first batch of production approval documents of the product were obtained by Chongqing shenghuaxi and xinlitai of Beijing New Pharmaceutical Co., Ltd Zhejiang Jingxin Pharmaceutical Co., Ltd was founded in 2001, only three years after its establishment, it was listed on the small and medium-sized board of Shenzhen Stock Exchange In 2016, the company achieved an operating revenue of 1.875 billion yuan, a year-on-year increase of 32.48%, and a net profit of 212 million yuan, a year-on-year increase of 28%.